Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 11, 2016, Pages 1367-1380

  Pafili, Kalliopi ^a   Maltezos, Efstratios ^a   Papanas, Nikolaos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Oral hypoglycemic agents; pharmacodynamics; pharmacokinetics; SGLT2 inhibitors; tofogliflozin

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE DERIVATIVE; LIPID; TOFOGLIFLOZIN; URIC ACID;

ALBUMINURIA; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BONE DENSITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHEMICAL STRUCTURE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; CYSTITIS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KIDNEY TUBULE ABSORPTION; LACUNAR STROKE; LIPID STORAGE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC PARAMETERS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYURIA; POSTMARKETING SURVEILLANCE; POSTPRANDIAL HYPERGLYCEMIA; POSTPRANDIAL PLASMA GLUCOSE; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SEPSIS; SODIUM ABSORPTION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME; WEIGHT REDUCTION;

EID: 84986211840     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1229302     Document Type: Article

References (122)

1. Number (in Millions) of civilian, noninstitutionalized persons with diagnosed diabetes, United States, 1980–2014. [cited 2015 Mar11]. Available from:http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
2. K.Pafili, N.Papanas, E.Maltezos Treatment of diabetic complications:how can we learn by seeking and blundering? Angiology. 2015;66:301–303.
3. E.W.Gregg, Y.Li, J.Wang, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–1523.
4. Anonymous. Diabetes care and research in Europe:the Saint Vincent declaration. Diabet Med. 1990;7:360.
5. N.Papanas, E.Maltezos, M.Edmonds. St. Vincent declaration after 15 years or who cleft the devil’s foot? Vasa. 2006;35:3–4.
6. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycaemia in type 2 diabetes:a patient-centered approach. Diabetes Care. 2012;35:1364–1379.
7. K.Pafili, N.Papanas. The importance of patient compliance with insulin pens:how can a new user-friendly pen help? Expert Opin Drug Deliv. 2014;11:629–632.
8. H.Vlassara, G.Striker. AGE restriction in diabetes mellitus:a paradigm shift. Nat Rev Endocrinol. 2011;7:526–539.
9. K.Pafili, N.Papanas, E.Maltezos. Gevokizumab in type 1 diabetes mellitus:extreme remedies for extreme diseases? Expert Opin Investig Drugs. 2014;23:1277–1284.
10. C.Cavelti-Weder, A.Babians-Brunner, C.Keller, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35:1654–1662.
11. N.Katsiki, N.Papanas, V.A.Fonseca, et al. Uric acid and diabetes:is there a link? Curr Pharm Des. 2013;19:4930–4937.
12. N.Katsiki, A.Karagiannis, D.P.Mikhailidis. Diabetes, bilirubin and amputations:is there a link? Diabetologia. 2013;56:683–685.
13. V.G.Athyros, N.Katsiki, A.Karagiannis, et al. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des. 2014;20:6299–6305.
14. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
15. R.K.Ghosh, S.M.Ghosh, S.Chawla, et al. SGLT2 inhibitors:a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457–463.
16. L.Blonde. State of diabetes care in the United States. Am J Manag Care. 2007;13(Suppl 2):S36–40.
17. R.C.Turner, C.A.Cull, V.Frighi, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama. 1999;281:2005–2012.
18. D.Vasilakou, T.Karagiannis, E.Athanasiadou, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetesa systematic review and meta-analysis. Ann Intern Med. 2013;159:262–267.
19. S.Goring, N.Hawkins, G.Wygant, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy:a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16:433–442.
20. T.Yang, M.Lu, L.Ma, et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus:a meta-analysis. Eur J Clin Pharmacol. 2015;71:1325–1332.
21. E.S.Mearns, D.M.Sobieraj, C.M.White, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes:a network meta-analysis. PLoS ONE. 2015;10:e0125879.
22. A.Liakos, T.Karagiannis, E.Athanasiadou, et al. Efficacy and safety of empagliflozin for type 2 diabetes:a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
23. A.Berhan, A.Barker. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus:a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58.
24. M.Monami, C.Nardini, E.Mannucci. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes:a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–466.
25. E.S.Mearns, W.J.Saulsberry, C.M.White, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes:a network meta-analysis. Diabet Med. 2015;32:1530–1540.
26. C.Clar, J.A.Gill, R.Court, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:e001007.
27. K.Pafili, N.Papanas. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors:no enemy but time? Expert Opin Pharmacother. 2015;16:453–456.
28. D.S.Shyangdan, O.A.Uthman, N.Waugh. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus:a systematic review and network meta-analysis. BMJ Open. 2016;6:e009417.
29. S.Matthaei, K.Bowering, K.Rohwedder, et al.; Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea:a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38:365–372.
30. M.A.Nauck. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
31. K.Katsuno, Y.Fujimori, Y.Takemura, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–330.
32. A.P.Sykes, G.L.Kemp, R.Dobbins, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17:98–101.
33. Licence Agreement of SGLT2 Inhibitor “CSG452” in Japan. [cited 2016 May06]. Available from:http://www.chugai-pharm.co.jp/hc/ss/downloads/121026eCSG452.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3D121026eCSG452.pdf&blobwhere=1396858107119&ssbinary=true.
34. B.Haas, N.Eckstein, V.Pfeifer, et al. Efficacy, safety and regulatory status of SGLT2 inhibitors:focus on canagliflozin. Nutr Diabetes. 2014;4:e143.
35. TOFOGLIFLOZIN. [cited 2016 Feb 5]. Available from:https://pubchem.ncbi.nlm.nih.gov/compound/tofogliflozin#section=Top.
36. (1S,3ʹR,4’S,5’S,6ʹR)-6-(4-Ethylbenzyl)-6ʹ-(hydroxymethyl)-3ʹ,4ʹ,5ʹ,6ʹ-tetrahydro-3H-spiro[2-benzofuran-1,2ʹ-pyran]-3ʹ,4ʹ,5ʹ-triol. [cited 2016 Apr20]. Available from:http://www.chemspider.com/Chemical-Structure.28530778.html
37. T.Sato, T.Kobayashi, M.Nishimoto, et al. (2010) Discovery of O-spiroketal C-arylglucosides as novel and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Scientific Abstracts for the 240th National ACS Meeting and Exposition; 2010 Aug22–26; Boston, MA. Washington, DC:American Chemical Society; p. MEDI–202.
38. Compound report card. [cited 2016 Apr20]. Available from:https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110731.
39. Efficay of SGLT2 inhibitors on bone mineral density in Japanese patients with type 2 diabetes. [cited 2016 Aug21]. Available from:http://www.easdvirtualmeeting.org/resources/efficacy-of-sglt2-inhibitors-on-bone-mineral-density-in-japanese-patients-with-type-2-diabetes–3.
40. Y.Ishibashi, T.Matsui, S.Yamagishi. Tofogliflozin, a highly selective inhibitor of sglt2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48:191–195.
41. E.Sugaru, T.Nakagawa, M.Ono-Kishino, et al. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. Am J Nephrol. 2006;26:50–58.
42. A.Merovci, C.Solis-Herrera, G.Daniele, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
43. J.J.Cohen, F.Berglund, W.D.Lotspeich. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 1956;184:91–96.
44. M.Suzuki, K.Honda, M.Fukazawa, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692–701.
45. T.Nagata, T.Fukuzawa, M.Takeda, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013;170:519–531.
46. A.Tahara, T.Takasu, M.Yokono, et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016;130:159–169.
47. S.Ikeda, Y.Takano, O.Cynshi, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:984–993.•• A very important study on the efficacy, safety, and tolerability of different doses of tofogliflozin in T2DM patients.
48. J.J.Devenny, H.E.Godonis, S.J.Harvey, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20:1645–1652.
49. Y.Liang, K.Arakawa, K.Ueta, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7:e30555.
50. K.Kaku, H.Watada, Y.Iwamoto, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus:a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.•• A very important study on the efficacy and safety of tofogliflozin 24-week monotherapy in T2DM Japanese patients.
51. K.Pafili, N.Papanas. Tofogliflozin:the road goes ever on. Expert Opin Pharmacother. 2014;15:1197–1201.
52. Y.Tanizawa, K.Kaku, E.Araki, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus:multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749–766.•• A very important study on the 52-week safety and efficacy of tofogliflozin in Japanese T2DM patients, which comprised a single-agent and an add-on trial.
53. L.Zhang, Y.Feng, J.List, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus:effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–516.
54. T.Kadowaki, S.Ikeda, Y.Takano, et al. Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone. Diabetes. 2012;61(Suppl. 1):A22.
55. J.P.Wilding, V.Woo, N.G.Soler, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin:a randomized trial. Ann Intern Med. 2012;156:405–415.
56. V.A.Fonseca, E.Ferrannini, J.P.Wilding, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268–273.
57. G.Schernthaner, J.L.Gross, J.Rosenstock, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
58. M.Suzuki, M.Takeda, A.Kito, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;4:e125.
59. P.Sengupta. The laboratory rat:relating its age with human’s. Int J Prev Med. 2013;4:624–630.
60. A.Obata, N.Kubota, T.Kubota, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157:1029–1042.
61. B.L.Finlay, R.B.Darlington. Linked regularities in the development and evolution of mammalian brains. Science. 1995;268:1578–1584.
62. M.J.Jurczak, H.-Y.Lee, A.L.Birkenfeld, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890–898.
63. A.Ojima, T.Matsui, Y.Nishino, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47:686–692.
64. U.Panchapakesan, K.Pegg, S.Gross, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One. 2013;8:e54442.
65. M.D.Breyer, E.Böttinger, F.C.Brosius3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27–45.
66. M.J.Soler, M.Riera, D.Batlle. New experimental models of diabetic nephropathy in mice models of type 2 diabetes:efforts to replicate human nephropathy. Exp Diabetes Res. 2012;2012:616313.
67. Y.Ohtake, T.Sato, T.Kobayashi, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–7840.
68. M.Yamane, K.Kawashima, K.Yamaguchi, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2015;45:230–238.
69. D.Schwab, A.Portron, Z.Backholer, et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet. 2013;52:463–473.
70. M.Zell, C.Husser, O.Kuhlmann, et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica. 2014;44:369–378.
71. SGLT2 inhibitor versus sulfonylurea on type 2 diabetes with NAFLD. [cited 2016 May2]. Available from:https://clinicaltrials.gov/ct2/show/NCT02649465?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=3.
72. Metabolic and cardiovascular effects of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) inhibitors. [cited 2016 Feb5]. Available from:https://clinicaltrials.gov/ct2/show/NCT02528019?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=4.• Important study on the effects of DPP-4 or SGLT-2 inhibitors on the metabolic cardiovascular systems in patients with T2DM.
73. Meta-analysis in post-marketing surveillances for SGLT2 inhibitors in patients with type 2 diabetes mellitus. [cited 2016 Feb5]. Available from:https://clinicaltrials.gov/ct2/show/NCT02284269?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=5.• Important meta-analysis, which integrates post-marketing surveillances data of the six SGLT-2 inhibitors approved or applied in Japan and evaluates the safety and efficacy of long-term use of each under actual clinical practice conditions.
74. V.G.Athyros, K.Tziomalos, N.Katsiki, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update. World J Gastroenterol. 2015;21:6820–6834.
75. Tofogliflozin GLP-1 analogue combination trial. [cited 2016 May4]. Avaialble from: https://clinicaltrials.gov/ct2/show/record/NCT02537834?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=1.
76. TOFO insulin combination trial. [cited 2016 May4]. Available from:https://clinicaltrials.gov/ct2/show/record/NCT02201004?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=2.
77. K.Yamaguchi, M.Kato, M.Suzuki, et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat:a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther. 2013;345:52–61.
78. T.Nagata, M.Fukazawa, K.Honda, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304:E414–23.
79. T.Nagata, M.Suzuki, M.Fukazawa, et al. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys. Am J Physiol Renal Physiol. 2014;306:F1520–33.
80. K.Yamaguchi, M.Kato, K.Ozawa, et al. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci. 2012;101:4347–4356.
81. Europe, US, Japan:the recall round-up. [cited 2016 May6]. Available from:http://www.in-pharmatechnologist.com/Regulatory-Safety/Europe-US-Japan-The-recall-round-up.
82. Summary of investigation results. Sodium-glucose co-transporter 2 (SGLT2) inhibitors. [cited 2016 May6]Available from:https://www.pmda.go.jp/files/000207393.pdf.
83. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL):A 12-week interim analysis. [cited 2015 May6]. Available from:http://onlinelibrary.wiley.com/doi/10.1111/jdi.12513/pdf.•• A very important study prospective observational study designed to investigate the safety and effectiveness of tofogliflozin hydrate in real-world patients with type 2 diabetes aged 65 years and older during the early post-marketing period.
84. E.M.Gibbs, J.L.Stock, S.C.McCoid, et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest. 1995;95:1512–1518.
85. J.M.Lenhard, M.E.Lancaster, M.A.Paulik, et al. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia. 1999;42:545–554.
86. N.Inagaki, K.Kondo, T.Yoshinari, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
87. K.Stenlöf, W.T.Cefalu, K.A.Kim, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
88. K.Kaku, S.Inoue, O.Matsuoka, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control:a Phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–440.
89. W.N.Washburn, S.M.Poucher. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2013;22:463–486.
90. E.C.Chao, R.R.Henry. SGLT2 inhibition— a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–559.
91. E.M.Wright, D.D.Loo, B.A.Hirayama. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
92. V.Vallon, K.A.Platt, R.Cunard, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–112.
93. C.S.Hummel, C.Lu, D.D.Loo, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C14–21.
94. J.J.Liu, T.Lee, R.A.DeFronzo. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61:2199–2204.
95. V.Vallon. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1009–22.
96. B.Komoroski, N.Vachharajani, D.Boulton, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
97. R.A.DeFronzo, M.Hompesch, S.Kasichayanula, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169–3176.
98. G.Musso, R.Gambino, M.Cassader, et al. A novel approach to control hyperglycemia in type 2 diabetes:sodium glucose co-transport (SGLT) inhibitors:systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
99. A.K.Patel, V.Fonseca. Turning glucosuria into a therapy:efficacy and safety with SGLT2 inhibitors. Curr Diabetes Rep. 2010;10:101–107.
100. E.K.Hussey, R.L.Dobbins, R.R.Stoltz, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects:a randomized double-blind study. J Clin Pharmacol. 2010;50:636–646.
101. FDA drug safety communication:FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [cited 2016 Mar2]. Available from:http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
102. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. [cited 2016 Mar2]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f.
103. S.I.Taylor, J.E.Blau, K.I.Rother. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
104. A.K.Singh. Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis:wisdom of hindsight. Indian J Endocrinol Metab. 2015;19:722–730.
105. S.Kalra, R.Sahay, Y.Gupta. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015;19:524–528.
106. M.Yokono, T.Takasu, Y.Hayashizaki, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66–74.
107. T.Fukao, G.D.Lopaschuk, G.A.Mitchell. Pathways and control of ketone body metabolism:on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids. 2004;70:243–251.
108. E.Ferrannini, E.Muscelli, S.Frascerra, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
109. P.M.Martin, E.Gopal, S.Ananth, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006;98:279–288.
110. N.B.Ruderman, P.S.Ross, M.Berger, et al. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J. 1974;138:1–10.
111. R.Nishimura, T.Osonoi, H.Jinnouchi, et al. Low carbohydrate did not affect the behaviour of luseogliflozin, a selective SGLT2 inhibitor on glycemic control over 24 hours measured by continuous glucose monitoring in Japanese patients with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 948.
112. H.Nakayama, S.Yoshinobu, S.Kawano, et al. Factors associated with the effect of ipragliflozin on the diurnal profiles of plasma glucose and 3-hydroxybutyrate in patient with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 1236.
113. C.Bonner, J.Kerr-Conte, V.Gmyr, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
114. E.Ferrannini. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise:a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217–2224.
115. J.F.List, V.Woo, E.Morales, et al. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657.
116. FDA drug safety communication:FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. [cited 2015 Jun1]. Available from:http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm.
117. D.E.Kohan, P.Fioretto, W.Tang, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
118. S.I.Taylor, J.E.Blau, K.I.Rother. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
119. A.J.Garber, M.J.Abrahamson, J.I.Barzilay, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
120. Y.Handelsman, Z.T.Bloomgarden, G.Grunberger, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
121. R.R.Henry, J.Rosenstock, S.Edelman, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes:a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412–419.
122. B.A.Perkins, D.Z.Cherney, H.Partridge, et al. Sodiumglucose cotransporter 2 inhibition and glycemic control in type 1 diabetes:results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.